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a b s t r a c t
Quinoxaline is a chemical compound that presents a structure that is similar to quinolone antibiotics. The 
present work reports the study of the antimicrobial activity of quinoxaline N,N-dioxide and some derivatives against 
bacterial and yeast strains. The compounds studied were quinoxaline-1,4-dioxide (QNX), 2-methylquinoxaline-1,4-
dioxide (2MQNX), 2-methyl-3-benzoylquinoxaline-1,4-dioxide (2M3BenzoylQNX), 2-methyl-3-benzylquinoxaline-1,4-
dioxide (2M3BQNX), 2-amino-3-cyanoquinoxaline-1,4-dioxide (2A3CQNX), 3-methyl-2-quinoxalinecarboxamide-1,4-dioxide 
(3M2QNXC), 2-hydroxyphenazine-N,N-dioxide (2HF) and 3-methyl-N-(2-methylphenyl)quinoxalinecarboxamide-1,4-dioxide 
(3MN(2MF)QNXC). The prokaryotic strains used were Staphylococcus aureus ATCC 6538, S. aureus ATCC 6538P, S. aureus ATCC 29213, 
Escherichia coli ATCC 25922, E. coli S3R9, E. coli S3R22, E. coli TEM-1 CTX-M9, E. coli TEM-1, E. coli AmpC Mox-2, E. coli CTX-M2 e E. coli 
CTX-M9. The Candida albicans ATCC 10231 and Saccharomyces cerevisiae PYCC 4072 were used as eukaryotic strains. For the 
compounds that presented activity using the disk diffusion method, the minimum inhibitory concentration (MIC) was determined. The 
alterations of cellular viability were evaluated in a time-course assay. Death curves for bacteria and growth curves for S. cerevisiae PYCC 
4072 were also accessed. The results obtained suggest potential new drugs for antimicrobial activity chemotherapy since the MIC’s 
determined present low values and cellular viability tests show the complete elimination of the bacterial strain. Also, the cellular 
viability tests for the eukaryotic model, S. cerevisiae, indicate low toxicity for the compounds tested.. Introduction
Antimicrobial agents are largely used in treatment and pre-
ention of microorganism infections. Among others, the misuse
nd, especially, the abusive use of this kind of drugs, in human
ealth, veterinary and animal production, led to the development
f drug-resistant and multidrug-resistant (MDR) microorganisms
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c Centro de Farmacologia e Biopatologia Química (U38-FCT), Faculdade de Medicina, Univ
Porto, Portugal
d CHUC, Centro Hospitalar da Universidade de Coimbra, Coimbra, Portugal
ith some antimicrobial drugs, besides the resistance develop-
ent, allows the increase of allergies and respiratory complications
hich are affecting the human population worldwide (Santos et al.2007; Vollaard and Clasener 1994; Butaye et al. 2001; Witte et al.
2008). Resistant bacteria are increasing and the interval between
the appearances of new and multi-drug resistant species is hap-
pening in short periods of time (Alanis 2005). These conditions
are becoming emergent public health issues in the sense that they
compromise pharmacological activity and the efficacy of these
antimicrobial agents (Fernandes et al. 2008, 2009) and thus the
heath of the population.
Because MDR bacteria are increasing worldwide human kind
deals with the urgent need of development of new drugs with
enhanced antimicrobial activity able to fight pathogens with no
adverse effects (Fernandes et al. 2013). It is also expected todevelop
drugs that can reverse the resistance observed overturning the6 Caparica, Portugal
la Superior de Tecnologias da Saúde, Instituto Politécnico do
ersidade do Porto, Alameda Prof. Hernâni Monteiro, 4200-319
actual bacterial profile. Some approaches have been developed in
order to evaluate the bioactivity of numerous compound families
against several strains of microorganisms (Gradelski et al. 2001;
Moellering 2011).
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fQuinoxaline is an organic heterocyclic compound that has been
sed as base of synthesis of bioactive derivatives and several inves-
igation groups have demonstrated their potential in medical and
harmacological applications (Zanetti et al. 2005; Carta et al. 2002;
anna et al. 1999). These studies point to chemotherapeutical
nterests regarding the anti-tumor, anti-bacterial, anti-fungal, and
nti-viral including anti-HIV (De Clercq 1997; Waring et al. 2002;
aykal et al. 2008; Harakeh et al. 2004) applications of these com-
ounds. Relevant bioactivity has been reported in Mycobacterium
pp. strains (Zanetti et al. 2005). No studies were found reporting
iological activity for the quinoxaline derivatives in the present
tudy with the microbial strains used.
The quinoxaline derivatives with N-oxide and N,N-dioxide have
articular interest since they present relevant anti-oxidant activ-
ty.Many compoundswith nitrogen oxygen bonds play important
iological roles by releasingNOgroupsorby cellular deoxygenating
Burguete et al. 2011; Hossain et al. 2012).
The present study pretends to be a contribution to the
haracterization of antibacterial and antifungal activity some N,N-
uinoxaline derivatives (Table 1).
The activity of these compounds was tested against bacteria
nd yeast in order to understand the biological activity in both
ukaryotic and prokaryotic microbial models. In the present work
accharomyces cerevisiae and Candida albicans were used as repre-
entative models of eukaryotic microorganisms. Likewise, several
trains of Staphylococcus aureus and Escherichia coli were used as
rokaryotic representative models of Gram-positive and Gram-
egative respectively.
. Material and methods
.1. Quinoxaline N,N-dioxide and quinoxaline derivatives
The compounds used in the present study were previously used
y some of our collaborators and were gently provided by the
enter of Investigation in Chemistry of the University of Porto.
ynthesis, spectra and thermochemical properties were already
tudied for the quinoxaline derivatives used in the present study
Table 1) (Acree et al. 1997; Ribeiro da Silva et al. 2004; Gomes et al.
005, 2007).
Stock solutions of the compounds were prepared in a 500mL
olume at a 500g/L final concentration. Since the compounds are
hermally stable, the solutions were sterilized in an autoclave (AJC
niclave 88) for 20min at 120 ◦C. From these solutions, standards
ere prepared at the final concentrations 500, 100, 50, 20, and
g/L.
.2. Bacterial strains
The strains used in this study were stored deep frozen at −80 ◦C.
he selected strains, in order to evaluate the susceptibility of a bac-
erial cell model to the proposed compounds, included S. aureus
TCC 6538, S. aureusATCC 6538P, S. aureusATCC 29213, E. coliATCC
5922, E. coli S3R9 and E. coli S3R22 (a penicillin resistant strain and
multidrug resistant strain, respectively). It was included some
. coli strains harboring extended spectrum -lactamases (ESBL)
uch as TEM-1, TEM-1+CTX-M9, CTX-M2, CTX-M9 and the AmpC
-lactamase MOX-2.
.3. Yeast strainsThe strains used in this study were S. cerevisiae PYCC 4072 (UNL,
ortugal) and C. albicans ATCC 10231 and were also stored deep-
rozen at −80 ◦C.2.4. Microorganisms culture and zone inhibition
In order to assess the potential microbial activity of the com-
pounds presented, disk diffusion method was used with two
purposes. The first one was to determine the sensibility of the
strains toknownantibiotics, cefoxitin (FOX)andciprofloxacin (CIP).
The second was to assess the inhibition zone for new compounds.
Bacteria and yeast cells were sub-cultured in broth agar (tryptic
soy broth – TSB) and incubated for 24h at 37 ◦C. Freshly prepared
bacterial cells were transferred into a saline solution (NaCl 0.9%,
Carlo Erba Reactifs, France) and density was settled in the interval
0.09 and 0.10, corresponding to 0.5 McFarland (1–2×108 CFU/mL).
The density of the solutions was measured at 625nm using a
spectrophotometer (Thermo Scientific Genesys 20). Solutionswere
spread onto a Trypticase Soy Agar (TSA; Cultimed, Spain) nutrient
plate in a laminarflowcabinet. Yeast strainswere spreadontoYeast
Extract Peptone Dextrose (YEPD; Oxoid, Basingstoke, UK) nutrient
plate, in laminar flow cabinet. Blank sterile disks were immersed
in the standard solutions, with the final concentration of 500, 100,
50, 20, and 5g/L for each compound. Plates were incubated for
24h at 37 ◦C and zone inhibition diameters were measured in mil-
limeters. Each one of these bacteria was tested with cefoxitin disks
(FOX) 30g and ciprofloxacin (CIP) 5g. Cefoxitin is a -lactam
and ciprofloxacin is a quinolone that has a similar structure of
quinoxaline. The compounds studied have no established reference
values regarding the sensitive/resistant behavior for the quinoxa-
line derivatives, so microdilution method was employed in order
todeterminedeminimuminhibitory concentration. Strains studied
were classified (Table 2) as susceptible (S) or resistant (R) accord-
ing to Clinical Laboratory Standard Institute (CLSI) guidelines, by
disk diffusion, considering the values of CLSI to the -lactam and
quinolone used in the present study. All results were confirmed by
replica.
2.5. Minimum inhibitory assays
The minimum inhibitory concentration (MIC) for each quinox-
aline derivative was estimated using the microdilution method,
according to the CLSI (Rex, 2009; Wilder 2005, 2006). The MIC’s
were determined for each strain/compound pairs that presented
antimicrobial activity.
The microplates used consisted of 96 wells. The TSB was dis-
pensed into several wells, 8 for each chemical compound. One of
these 8 wells corresponded to the positive control (containing the
culture medium and bacterial suspension) and another to the neg-
ative control (containing only the culture medium). The remaining
wells were used to prepare volumetrically diluted in series from
stock solution (1:1, 1:2, 1:4, 1:8, 1:16 and 1:32) for each compound
and considering the concentrations that presented inhibition halo.
Fresh prepared cultures of the microorganisms were suspended in
a saline solution to a density of 0.100 at 625nm. Each well was pre-
pared to a final volume of 200L. The microplates were closed and
incubated at 37 ◦C, for 16–20h. The presence or absence of turbid-
itywas verified and rechecked by inoculating a fraction of thewells
in solid culture medium (Mueller-Hinton broth, Cultimed, Spain).
The plates were incubated for 24h at 37 ◦C. The results obtained in
the wells and plates were compared. All results were confirmed by
replica.
2.6. Cellular viability of bacteria
In order to evaluate the growing or death performance cel-
lular viability was analyzed for all strain/quinoxaline derivative
pairs that presented growth inhibition and for which MIC’s were
determined.Microbial suspensionswerepreparedat 0.5McFarland
density with TSB medium for bacterial strains. The solutions of
the studied compounds were colored and the optical density (OD)
Table 1
Quinoxaline N,N-dioxide and quinoxaline derivatives.
Quinoxaline-1,4-dioxide (QNX) 2-Methylquinoxaline-1,4-dioxide
(2MQNX)
2-Methyl-3-benzoylquinoxaline-1,4-dioxide
(2M3BenzoilQNX)
2-Methyl-3-benzylquinoxaline-1,4-dioxide
(2M3BQNX)
2-Amino-3-cyanoquinoxaline-1,4-dioxide
(2A3CQNX)
3-Methyl-2-quinoxalinecarboxamide-1,4-dioxide
(3M2QNXC)
2-Hidroxiphenazine-N-dioxide (2HF) 3-Methyl-N-(2-methylphenyl)
quinoxalinecarboxamide-1,4-dioxide
(3MN(2MF)QNXC)
Table 2
Zone diameter interpretative Standards (Enterobacteriaceae) and equivalent minimal inhibitory concentration (MIC) according to CLSI document (Wilder 2005).
Zone diameter interpretative standards (mm) MIC (g/mL)
R I S R S
Ciprofloxacin (CIP) (5g) ≤15 16–20 ≥21 ≥4 ≤1
Cefoxitin (FOX) (30g) ≤14 15–17 ≥18 ≥32 ≤8
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D– resistant; I – intermediate; S – susceptible.
easurements lack accuracy. In alternative to the construction of
ellular viability and death curves by platting was observed in a
ime-course assay. For 24h, the presence of viable cells was tested
nd CFU/mL was determined. The time intervals were divided
s presented in Table 3. A standard tube containing the studied
train and growing media was used as control and a test tube con-
aining also the quinoxaline derivative in the MIC concentration
etermined previously was used as working solution. For CFU/mL
ounting, optimum dilution was determined by serial dilutions
ith 10−1 factor, in saline solution, adding 1/10 of strain media
nd 9/10 of saline solution (Table 3). All results were confirmed by
eplica..7. Cellular viability for eukaryotic model
The aim of this method was to evaluate the cellular viabil-
ty effects of compounds that presented antibacterial activity. The
able 3
ilution factor and time intervals for UFC/mL determinations.
Optimum dilution factor Time for counting (min)
Bacteria 10−5 0 30 60
Yeast 10−3 0 30 60procedure was the same as described for bacteria, but the final
concentration of compounds was 500g/L, corresponding to the
highest MIC determined previously. Along 24h, CFU/mL was deter-
mined if viable cells were present. The time intervals were divided
as presented in Table 3. All results were confirmed by replica.
3. Results and discussion
3.1. Disk diffusion method
The quinoxaline derivative compounds studied have no ref-
erence values for the disk diffusion method, according to CLSI.
Nevertheless, CLSI guidelines were used for known antibiotics.
For the results obtained by this method, the absence of inhibi-
tion zone for the compounds tested was considered an indicative
of no antimicrobial activity against that strain. Table 4 shows
90 120 180 1440
90 120 180 210 1440
Table 4
Disk diffusion diameters for the quinoxaline derivatives.
Strain Compound (500g/L)
QNX 2MQNX 2M3BenzoilQNX 2M3BQNX 2A3CQNX 3M2QNXC 2HF 3MN(2MF)QNXC
Inhibition halo/mm
S. aureus ATCC 6538
S. aureus ATCC 6538P
S. aureus ATCC 29213
0
E. coli ATCC 25922 0 0 0 0 11 24 0 0
E. coli S3R9 0 0 0 0 16 26 0 0
E. coli S3R22 0 0 0 0 24 26 0 0
E. coli TEM-1 CTX M9 0 0 0 0 0 14 0 0
E. coli TEM-1 24 16 0 0 16 26 14 0
E. coli AmpC MOX-2 0 0 0 0 0 15 0 0
E. coli CTX M2
E. coli CTX M9
0
S. cerevisiae PYCC 4072
C. albicans ATCC 10231
0
Table 5
Classification of each strain as susceptible (S) or resistant (R) according to CLSI in
presenceof cefoxitindisk (FOX)andciprofloxacindisk (CIP) bydiskdiffusionmethod
(Wilder 2005).
Strain Antibiotic
Cefoxitin (30g) Ciprofloxacin (5g)
S. aureus ATCC 6538 S S
S. aureus ATCC 6538P R S
S. aureus ATCC 29213 S S
E. coli ATCC 25922 S S
E. coli S3R9 S S
E. coli S3R22 S R
E. coli TEM CTX-M9 S R
E. coli TEM-1 S S
E. coli AmpC MOX-2 R S
S. aureus: S – sensitive (CIP: zone inhibition≥21mm;FOX: zone inhibition≥22mm);
R – resistant (CIP: zone inhibition ≤15mm; FOX: zone inhibition <21mm).
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Table 6
Minimum inhibitory concentration (g/L) results for each group bacterial
strain/compound by microdilution method, CLSI (Wilder 2006).
Strain Compound Minimum inhibitory
concentration (g/L)
E. coli ATCC 25922
2A3CQNX 500
3M2QNXC 350
E. coli S3R9
2A3CQNX 320
3M2QNXC 125
E. coli S3R22
2A3CQNX 320
3M2QNXC 200
E. coli TEM CTX-M9 3M2QNXC 125
E. coli TEM-1
QNX 256
2MQNX 400
2A3CQNX 100
3M2QNXC 80
2HF 329. coli: S – sensitive (CIP: zone inhibition ≥21mm; FOX: zone inhibition ≥18mm);
– resistant (CIP: zone inhibition <15mm; FOX: zone inhibition <14mm).
ntimicrobial activity results for each bacterial or yeast strain and
ach compound tested. All the compounds studied showed no
ntimicrobial activity in the Gram-positive prokaryotic strains and
ukaryotic strains since no inhibition zone was observed. On the
ther hand, the compounds only presented antimicrobial activity
n Gram-negative prokaryotic strains, except for E. coli CTX-M2 and
. coli CTX-M9. The compound 2A3CQNX presented activity in four
ram-negative strains (E. coli ATCC 25922, E. coli S3R9, E. coli S3R22
nd E. coli TEM-1); whereas 3M2QNXC was the compound that
resented activity in a greater number of strains studied, namely,
. coli ATCC 25922, E. coli S3R9, E. coli S3R22, E. coli TEM-1 and
. coli AmpC MOX-2. The other compounds, QNX, 2MQNX and
HF only presented activity in E. coli TEM-1. Several studies refer
elective antibacterial activity. Meanwhile, others reveal activity
n both Gram-positive and Gram-negative cells (Sykes et al. 1982;
londeau et al. 2000; Neu and Labthavikul 1982). The results pre-
ented in Table 5 seem to indicate that E. coli S3R22 and E. coli TEM
TX-M9 are resistant to ciprofloxacin (5g) and E. coli AmpCMOX-
is resistant to cefoxitin (30g). The other strains, S. aureus and
. coli, seem to be sensitive to both antibiotics.
.2. Minimum inhibitory concentrationFor the compounds that presented activity using the disk diffu-
ion method, minimum inhibitory concentration (MIC) was deter-
inedandpresented inTable6. These results canbecomparedwithE. coli AmpC MOX-2 3M2QNXC 100
MIC values previously determined for cefoxitin and ciprofloxacin
and presented in Table 2 (Rex 2009). The results are presented for
each well, bacteria, growth medium and different concentrations
of each compound. The results were validated with both negative
(compound and growth medium that presented no turbidity) and
positive controls (bacteria and growth medium that presented tur-
bidity). The MIC values presented are smaller than those indicated
by the CLSI to CIP and FOX, suggesting a more effective activity of
quinoxaline derivatives with respect to those antibiotics.
3.3. Cellular viability and CFU variation for prokaryotic cells
Cellular viability was analyzed for all bacterial
strain/quinoxaline derivative pairs that presented growth inhibi-
tion by disk diffusion method and for which MIC’s were previously
determined. Fig. 1 shows an example of CFU/mL variation along
time for Gram-negative prokaryotic strain (E. coli TEM-1). The
results obtained show that every strain, in absence of any com-
pound, grows up in the first minutes (viable cells), as expected
(Chang-Li et al. 1988; Zwietering et al. 1990; Sezonov et al. 2007)
and then decreases the number of CFU/mL until 24h. For each
bacterial strain/quinoxaline derivative pairs, the number of viable
cells decreases with time, as expected, and at 24h there are no
viable cells. For E. coli TEM-1/2MQNX group the Fig. 1 shows that
there are no viable cells at 180min. CFU/mL variation for other
bacterial strains/quinoxaline derivative pairs presented a similar
behavior to E. coli in presence and absence of compounds.
Fig. 1. Example of variation for Gram negative prokaryotic strains (E. coli TEM-1) in the presence of quinoxaline derivative at MIC determined.
Fig. 2. Variation along time for S. cerevisiae in absence/presence of the compounds tested.
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e-.4. Cellular viability and CFU variation for eukaryotic cells
Both eukaryotic strains, C. albicans and S. cerevisiae, grow up
n the first minutes. This is followed by a decrease of cellular via-
ility (Barford 1990; Bochu et al. 2003). By exposing S. cerevisiae to
he compounds that presented antibacterial activity (QNX, 2MQNX,
M2QNXC, 2A3CQNX, 2HF), the number of viable cells calculated
y CFU increases in the time-course. as observed in Fig. 2. These
esults seem to indicate that, in the presence of these quinoxaline
erivatives, S. cerevisiae has a growth rate that increases. Surpris-
ngly, all the quinoxaline derivatives studied showed no effect on
rowth or cell viability, when compared with the control. Actually,
rowth enhanced rather than declined. Naturally, we do not have
t this point of the state of the art any explanation for these results,
hat we intend to clarify in further studies.
Nevertheless, it seems promising that compounds that may be
otential antimicrobial agents used in humans or veterinary, may
ot be toxic in eukaryotic cells.4. Conclusions
Quinoxaline derivative compounds studied in the present wor
presented selective antimicrobial activity between both eukaryot
and prokaryotic strains. Antimicrobial activity was observed on
in the Gram-negative strains studied, except in E. coli CTX-M2 an
E. coli CTX-M9. We believe that these two strains may encode som
kind of mechanism that confers resistance to this group of com
pound. No antimicrobial activity was observed for Gram-positiv
prokaryotic strains, possibly due to the presence of peptidoglyca
in Gram-positive cell wall, permeability properties of the mem
branes, or even due to metabolic dissimilarities between these tw
phylogenetic groups, that enables the entrance/activity of the com
pounds. This fact may also point to the need of these compounds
cross cellularwalls toact.At thepresent time, therearenoclues th
might explain why some quinoxaline derivatives have a distinctiv
behavior between G+ and G− inhibition.
Moreover,wealsohavenodata that supportswhy thosequinox
aline derivatives which present antibacterial activity promote
cerevisiae growth. The mode of action of these quinoxaline deriv
tives is not clear yet. We intend to develop further studies in ord
to contribute to this elucidation. The results showed in the presen
study, should guide these works. We now know that they see
not to be effective in yeast and in Gram positive strains. So, furth
studies on Gram negative response will be conducted. Since th
mechanism of action of these compounds is not known it is diffi
cult at this point of the state of the art to discuss structure activi
relationship based on cell viability studies.
With exception to 2M3BenzoylQNX and 3M3BQNX, that pr
sented no activity against the strains studied, all the compound
presented activity against both quinolone and/or -lactams Gram
negative resistant strains. The MIC values determined we
between 80 and 500g/L, and are smaller than the admitted value
for approved drugs with antibiotic activity (CIP and FOX) and wit
similar chemical constitution (CIP) (Table 2).
The cellular viability for the eukaryotic strain and the death ra
for the prokaryotic strains studied, at MIC concentrations, sugge
these compounds as potential new drugs with selective antibact
rial activity for Gram-negative bacteria.
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